New CAR-T therapy with IL-15 for treating blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates a novel CAR-T therapy that co-expresses IL-15 for patients with malignant hematological tumors, including acute lymphocytic leukemia and relapsed refractory multiple myeloma. It is a multicenter, single-arm, open-label study aiming to recruit 45 subjects. The primary focus is on assessing the safety and efficacy of this innovative treatment, while secondary objectives include investigating the in vivo survival time and the activation and proliferation of the CAR-T cells. Participants will receive chimeric antigen receptor gene modified T cells as the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* I (or the authorized representative/legal guardian) agree and have signed an informed consent form, and am willing and capable of following the planned visits, research treatments, laboratory tests, and other research procedures;
* Histopathological or flow cytometric diagnosis of CD19 and/or CD22, BCMA-positive hematological malignancies;

  -≥15 years old, ≤80 years old;
* If you meet one of the following three conditions, you can be included in the group:-Patients with recurrent or refractory hematologic malignancies treated with one standard chemotherapy regimen and one salvage regimen;-Minimal residual lesions persist after treatment with one standard chemotherapy regimen and one salvage regimen;-Patients with recurrence after hematopoietic stem cell transplantation;
* Estimated survival ≥12 weeks;
* Good heart, liver and kidney function:
* Serum creatinine ≤ 1.5 mg/dL (1mg/dl=88.4umol/L); Serum ALT/AST ≤ 2.5 ULN; Total bilirubin ≤ 1.5 mg/dl (1mg/dl=17.1umol/L):
* Cardiac ejection fraction ≥50%, cardiac ultrasound showed centropericardial effusion:
* Eastern Oncology Collaborative Group Activity Status Score (ECOG)0-3;
* Able to understand and voluntarily sign informed consent; If the subject is a child, the guardian will sign the informed consent.

If the answer to any of the above is \"no\", the subject will not be allowed to participate in this study.

Exclusion Criteria:

* Have a New York Heart Association (NYHA) classification \> Class III heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically prominent heart disease within one year prior to signing the consent form, or have a QTC interval \>480ms at the time of screening (QTC interval is calculated using the Fridericia formula);
* Have active GVHD, or need immunosuppressants;
* Other malignancies were present within 5 years prior to screening, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, and breast ductal carcinoma in situ after radical resection of local prostate cancer;
* The presence of an active or uncontrolled infection requiring systemic treatment (except for mild genitourinary and upper respiratory tract infections) in the 7 days prior to screening;
* If HBSAg or HbCAb positive peripheral blood hepatitis B virus (HBV)DNA is higher than the lower limit of detection, it should be excluded. If hepatitis C virus (HCV) antibody positive, peripheral blood HCVRNA positive should be excluded; (HIV) antibody-positive; -Cytomegalovirus (CMV)DNA test positive for human immunodeficiency virus; Those who test positive for Treponema pallidum specific antibody (TPPA) should be excluded;
* Participating in another clinical trial within 4 weeks prior to the signing of the informed consent, or the signing date of the informed consent is still within 5 half-lives of the drug (whichever is longer) since the last drug used in the last clinical trial;
* A history of severe allergy to biological products;
* Systemic diseases that are considered unstable by the investigator: including but not -limited to severe liver, kidney, or metabolic diseases requiring medical treatment;
* Pregnant or lactating women, and female subjects who plan pregnancy within 2 years after cell transfusion or male subjects whose partner plans pregnancy within 2 years after cell transfusion;
* Conditions that the investigator believes may increase the risk to the subject or interfere with the test results.

Where it's running

• Shanxi Bethune Hospital
  Taiyuan, Shanxi, China Recruiting

Study contacts

• Study coordinator: Jia Wei
• Email: ngc2237fh@163.com
• Phone: CHN13986102084

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• AZD0120 dual-target CAR-T (BCMA and CD19) versus standard treatments for relapsed refractory multiple myeloma

  This trial tests whether a dual-target CAR-T therapy called AZD0120 works better than commonly used drug regimens for adults with relapsed or refractory multiple myeloma.

  Recruiting at 40 sites Phase 3 AstraZeneca · Gilbert, Arizona and 142 other locations · NCT07391657

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• BCOR and ZC3H12 gene‑knockout CD19 CAR‑T therapy for adults with relapsed/refractory B‑cell ALL

  This will test whether autologous CD19‑targeting CAR‑T cells with BCOR and ZC3H12 genes knocked out can be safe and produce durable remissions in adults with relapsed or refractory B‑cell acute lymphoblastic leukemia.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Biotherapeutic Department of Chinese PLA General Hospital and 1 other locations · NCT07008885

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.